Novanta Inc. (NOVT) Stock Price & How to Invest
Short answer
You can invest in Novanta (NOVT) by buying shares or fractional shares at any major broker, through a small-cap or mid-cap growth or industrial ETF that holds it, or as one holding in a thematic basket. Novanta is a precision technology company that supplies photonics, vision, and precision motion components and sub-systems to medical and advanced industrial OEMs, and it trades as a high-quality, high-multiple compounder rather than a value or income name.
NOVT stock price
As of 2026-07-08, Novanta Inc. (NOVT) last closed at $148.59, up 12.1% over the past year. Over the past 52 weeks it has traded between $99.22 and $168.59.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Novanta Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Novanta Inc. (NOVT) do?
Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest.
Novanta grows through a mix of organic gains in its OEM franchises and a steady cadence of bolt-on acquisitions that add technology and expand its addressable market. The investment picture is that of a diversified precision-components compounder: modest single-digit organic growth in a typical year, higher reported growth when acquisitions are added, and expanding adjusted margins, all of which the market has historically rewarded with a premium valuation. The trade-off is that the stock's high price-to-earnings multiple makes it sensitive to any slowdown in medical or industrial capital spending, integration missteps, or margin pressure, so the shares can be volatile around earnings and macro shifts.
What's driving Novanta Inc. (NOVT)?
1. Medical Solutions demand.
The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Novanta supplies embedded photonics, motion, and radio-frequency technologies to medical-device OEMs, giving it exposure to durable healthcare spending trends. Demand here tends to be less cyclical than industrial markets, which supports steadier revenue.
2. Automation and robotics.
The Automation Enabling Technologies segment sells precision motion, machine vision, and laser components into robotics, industrial automation, and laser materials processing. Novanta reported strong bookings growth with a book-to-bill ratio above 1.0 in early fiscal 2026, pointing to recovering order momentum. This unit ties Novanta to long-run automation and reshoring themes, though it is more sensitive to the industrial capital-spending cycle.
3. Acquisitions and margin expansion.
Novanta has a long track record of bolt-on acquisitions that add proprietary technology, broaden its OEM relationships, and expand its addressable market. Management pairs this with a focus on adjusted EBITDA margin expansion and pricing discipline. Successful integration is central to the growth story, since much of the company's reported revenue growth in a given year can come from deals rather than pure organic gains.
4. Improving order momentum.
In its Q1 fiscal 2026 report, Novanta cited bookings up about 37% year over year with double-digit bookings and revenue growth across all business units, and it raised its full-year revenue and earnings outlook. Rising bookings and a book-to-bill above 1.0 suggest the backlog is building. Whether that momentum converts into sustained organic growth depends on end-market demand holding up.
What are the risks to Novanta Inc. (NOVT)?
Novanta trades at a high price-to-earnings multiple, so any shortfall in growth or margins can drive sharp share-price moves. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
How is Novanta Inc. (NOVT) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Novanta Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$1.0 billion
- Q1 FY2026 revenue: ~$258 million (up ~10% YoY)
- FY2026 revenue guidance: ~$1,040-1,055 million
- Adjusted EPS guidance (FY2026): ~$3.50-3.65
- Adjusted EBITDA guidance (FY2026): ~$245-250 million
- Market cap: ~$5.7 billion
- P/E (trailing): ~100x
- P/E (forward): ~41x
Novanta trades at a rich valuation, with a trailing price-to-earnings ratio near 100x and a forward multiple around 41x, reflecting the market's view of it as a durable, high-margin precision-technology compounder. GAAP earnings are held down by acquisition-related amortization and stock compensation, so the company and analysts emphasize adjusted EPS and adjusted EBITDA. That premium multiple means the shares can react strongly to any change in the growth or margin trajectory.
Who competes with Novanta Inc. (NOVT)?
Photonics and laser component makers
Companies like Coherent, IPG Photonics, MKS Instruments, and Lumentum compete in lasers, photonics, and laser materials processing where Novanta sells scanning and beam-steering components. These firms are generally larger and often supply higher-power or system-level laser products, while Novanta focuses on embedded precision sub-systems for OEMs.
Precision motion and vision suppliers
In precision motors, encoders, and machine vision, Novanta competes with players such as Cognex, Keyence, and various motion-control specialists. These companies also target industrial automation, robotics, and inspection markets where reliability and precision are the basis of competition.
Medical-device technology suppliers
Within its Medical Solutions segment, Novanta competes with other component and sub-system suppliers to medical-device OEMs across minimally invasive surgery, life sciences, and patient monitoring. Here the contest is over design wins inside customers' instruments, regulatory-grade quality, and long-term OEM relationships.
How to invest in Novanta Inc. (NOVT)
There are three common ways to get NOVT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NOVT sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where NOVT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Novanta Inc. (NOVT)
Novanta is a niche precision-technology supplier whose growth leans on medical and automation OEM demand plus bolt-on acquisitions, and it carries a rich earnings multiple that leaves little room for disappointment.
More on Novanta Inc. (NOVT)
Whether NOVT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NOVT a buy?, and where the stock could go from here in the NOVT stock forecast.
For income investors, whether NOVT pays a dividend and how the payout looks is covered in does NOVT pay a dividend?
Build a basket around NOVT with Walnut
Use Novanta Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Novanta do?
+
Novanta is a precision technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems. It sells these to original equipment manufacturers in medical and advanced industrial markets, where its parts are embedded inside customers' larger machines and instruments.
What are Novanta's business segments?
+
Novanta reports two segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and electronics manufacturing. Medical end markets are a bit over half of revenue and advanced industrial the rest.
How much revenue does Novanta generate?
+
Novanta generates roughly $1.0 billion in trailing-twelve-month revenue as of July 2026. Its Q1 fiscal 2026 revenue was about $258 million, up around 10% year over year, and management guided full-year 2026 revenue to roughly $1,040-1,055 million.
Does Novanta pay a dividend?
+
Novanta does not pay a regular dividend. The company reinvests its cash flow into research and development and bolt-on acquisitions to fund growth, so returns to shareholders have historically come from share-price appreciation rather than income.
Why is Novanta's P/E ratio so high?
+
Novanta's trailing price-to-earnings ratio sits near 100x because GAAP earnings are depressed by acquisition-related amortization and stock-based compensation, and because the market prices it as a durable, high-margin compounder. Its forward multiple, around 41x, is lower and analysts often focus on adjusted EPS.
Who are Novanta's main competitors?
+
Novanta competes with photonics and laser firms like Coherent, IPG Photonics, MKS Instruments, and Lumentum, with precision-motion and machine-vision players like Cognex and Keyence, and with other component suppliers to medical-device OEMs. Its niche is embedded precision sub-systems rather than full systems.
What are the main risks of investing in Novanta?
+
Key risks include a high valuation that magnifies any earnings disappointment, cyclical exposure to industrial and semiconductor capital spending, heavy reliance on acquisitions for growth, and customer-concentration and design-win risk since its products sit inside OEM machines. Tariffs, supply-chain costs, and currency swings can also pressure results.
How can I invest in Novanta stock?
+
Novanta trades on the Nasdaq under the ticker NOVT, so you can buy shares or fractional shares through any major brokerage. You can also gain exposure through mid-cap or industrial-technology ETFs that hold it, or by including it as one holding in a diversified thematic basket. Walnut is not an investment adviser, so consider your own goals and risk tolerance.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Novanta Inc.'s investor relations page or your broker before making investment decisions.